LCAT and Familial LCAT deficiency: Now that recombinant LCAT is being developed as a potential treatment for this disorder [22,39], it is important to determine if LpX is nephrotoxic and, therefore, can be used as a biomarker in FLD patients treated with recombinant LCAT.